Watch our webinar on-demand to learn how choosing an integrated service provider can help to accelerate your drug development timeline, featuring a customer case study from Ensysce Biosciences CEO, Lynn Kirkpatrick.
Many pharma and biotech companies are seeking new ways of making drug development more efficient and cost-effective in order to achieve their regulatory milestones faster. To meet this demand, the outsourcing services sector has scaled and grown, but in doing so, has become more siloed, with separate vendors each handling different activities – from medicinal chemistry, to preclinical studies, to clinical research, to product development and manufacturing. This separation of activities has created a more complex approach to drug development for sponsor companies, where there is a distinct lack of communication between the multiple vendors working on a particular drug molecule, leading to delayed timelines, increased risk and higher costs.
In this webinar presentation, Dr. Vanessa Zann, Senior Drug Development Consultant, will be joined by Lynn Kirkpatrick, CEO of Ensysce Biosciences, to discuss the benefits of Quotient Sciences' integrated drug development platform Translational Pharmaceutics®.
Watch this webinar on-demand
Ensysce Biosciences' PF614-MPAR is a novel opioid combination product for the potential treatment of chronic pain that is designed to prevent both abuse and overdose. It is currently in Phase I trials. Quotient Sciences has supported Ensysce Biosciences with an integrated formulation development and Phase I clinical study program for PF614.
Lynn Kirkpatrick, CEO of Ensysce Biosciences, will highlight the reasons why Ensysce Biosciences selected Quotient Sciences as an outsourcing partner. She will discuss her company's experience working with Quotient Sciences, and how the Quotient Sciences Translational Pharmaceutics platform for integrated drug development is being used for their program.
You'll hear about:
- How the Quotient Sciences Translational Pharmaceutics platform has accelerated Ensysce Biosciences' drug development timeline and what Ensysce hopes to achieve next through their partnership with Quotient Sciences
- How drug product formulations and doses can be adjusted and manufactured in real-time, often in response to emerging human data
- How the integration of drug substance, drug product & clinical testing activities under one organization can encourage close relationships between multidisciplinary experts and create a more agile approach to pharmaceutical development, which ultimately accelerates timelines towards IND and onwards to proof-of-concept.
Lynn Kirkpatrick, CEO of Ensysce Biosciences
Lynn Kirkpatrick is the CEO of Ensysce Biosciences, a clinical-stage biotech company based in San Diego, CA. Her professional background is in medicinal chemistry, pharmacology, drug discovery and drug product development. She has co-founded two start up companies in her career and has developed three targeted small molecule oncology drugs from discovery to the clinic. She has experience in both private and public companies raising funds from private, public and government sources.
Dr. Vanessa Zann, Senior Drug Development Consultant at Quotient Sciences
Vanessa has over two decades of industry experience providing biopharmaceutics support to discovery, development, and clinical programs. Prior to joining Quotient Sciences, Vanessa worked at AstraZeneca as a permeability expert in the Pharmaceutical Development department.